Page 246 - 北京京煤集团总医院第十届·2022学术年会论文集

北京京煤集团总医院 第十届·2022 学术年会论文集

[5] AHR N B P,MASMIQUEL L P,KUMAR H M,et al. Efficacy and safety of once-weekly

semaglutide versus once-daily sitagliptin as an add-on to metform- in,thiazolidinediones,or both,in

patients with type 2 diabetes ( SUSTAIN 2 ) : a 56-week,double-blind, phase 3a,randomised trial[J].
Lancet Diabetes & En- docrinology,2017,5( 5) : 341 - 354.

[6] ANDREW J,MATTHEW C,GUILLAUME C,et al. Efficacy and safety of once-weekly
semaglutide versus exenatide ER in subjects with type 2 diabetes( SUS- TAIN 3) : A 56-week,open-

label,randomized clinical trial[J]. Diabetes Care2018,41( 2) : 258 - 266.

VANITA R A,STEPHEN C,BERTRAND C,et al. Efficacy and safety of once-weekly semaglutide

versus once-daily insulin glargine as add-on to metformin with or without sulfonylureas) in insulin-

naive pa- tients with type 2diabetes( SUSTAIN 4) : a random- ised, open-label, parallel-group,

multicentre,multina- tional,phase 3a trial[J]. Lancet Diabetes & Endocri- nology, 2017,5( 5) : 355 -

366.

[7] RICHARD E P, VANITA R A, ILDIKO L, et al. Semaglutide versus dulaglutide once weekly

in patients with type 2 diabetes ( SUSTAIN 7 ) : a randomised, open-label,phase 3b trial[J]. The

Lancet Diabetes & Endocrinology,2018,6( 4) : 275 - 286.

[8] WILDING JPH, BATTERHAM RL, CALANNA S, et al. Once weekly semaglutide in adults
with overweight or besity[ J]. N Engl J Med, 2021, 384(11)989.

[9]RUBINO DM, GREENWAY FL, KHALID U, et al. Effect of weekly subcutaneo us semaglutide
vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP

8 randomizd clinical trial [ J]JAMA, 2012, 27 (2 ): 138 - 150.

[10]程速远, 李小静, 罗建辉. 胰高血糖素样肽⁃1 受体激动剂研究进展[J]. 中国新药杂志,

2020, 29(22): 2580 - 2585.

[11] 张文竹, 孙韬华, 石杰. 首个口服胰高血糖素样肽 1 受体激动剂索马鲁肽[J]. 中国新药

杂志,2020,29(22): 2552 - 2556.

[12] newsomepn, buchholtz k, cusi k, et al. a placebo controlled trial of sbcutaneous semaglutide in

nonalcoholic steatohepatitis

- 241 -